Dr. Falk Pharma Pricing and Market Access Sustainability Policy
 

Dr. Falk Pharma is committed to sustainable practices. As we prepare to comply with the European Corporate Sustainability Reporting Directive (CSRD) and the European Sustainability Reporting Standards (ESRS) from 2025 onwards, the following Statement outlines our plans for sustainability in relation to pricing and market access.

Our Pricing and Market Access Sustainability Policy is guided by our vision of ‘together more knowledge, more innovation, more life’. We seek to create value beyond the impact of our medicines by embedding sustainability into everything we do – from our innovative research in digestive and metabolic diseases to ensure patient access. We aim to improve healthcare access for individuals with digestive and metabolic diseases by offering innovative, sustainable, and affordable care. In line with our goals of giving access to medicines and providing sustainable and affordable pricing, we focus on two primary areas:

• Equitable access: Working closely with healthcare systems, payers, and partners to promote equitable access and allow patients and society to benefit from medicines across our entire product portfolio
   
• Pricing and sustainability: Promoting access to medicines for diverse, equitable, and inclusive patient populations through comprehensive company policies and programs, including core pricing principles and access programs

We believe everyone should have access to healthcare, regardless of their identity or location. This is essential throughout patient care, from prevention, early detection, and diagnosis to effective treatment of disease. In the countries where we operate, the focus is on ensuring that all patients who need our medicines can access them in a way which is sustainable for patients, society, and Dr. Falk Pharma.

Every person has a right to health, and health should not be determined by who you are, where you live or where you were born. Many challenges may hinder access to medicines, including the lack of healthcare professionals close to patients, new medicine reimbursement delays, and affordability and availability issues.

As a global business, various factors impact our ability to provide access to our medicines, including pricing controls, reimbursement mechanisms, taxation, and mark-up systems, as well as frequent regulatory changes. Additionally, supply chain complexity can increase costs, while the economic downturn may impair the ability to pay. To overcome these challenges, it is essential that our industry, policymakers and payers collaborate to identify new solutions. 

We consider equity and sustainability in our pricing approach. Understanding the challenges that healthcare systems and patients face in terms of equity and affordability, we adopt a flexible approach to reflect the diversity of different healthcare systems. We are dedicated to working with patients, policymakers, payers, and the healthcare community to ensure access to our medicines is as equitable, widespread, and sustainable as possible.

Scope of the focus area
We work closely with healthcare systems, payers, and partners to drive equitable access and ensure patients and society benefit from medicines across our entire product portfolio. This includes promoting diversity in clinical trials, focusing on patient needs, investing in rare digestive and metabolic diseases, and encouraging innovation. 

Strategic approach
We recognize that our role in society extends beyond discovering and developing treatments for digestive and metabolic diseases. The real difference will come from ensuring that these treatments can reach patients wherever they live. This is why we are committed to improving equitable access to healthcare worldwide and continuously strive to innovate and develop new solutions that contribute to real improvements in patient health. 

Currently, Dr. Falk Pharma is present in over 65 countries, ensuring its medical products are close to those in need of treatment. We contribute to ensuring that all patients who need our medicines have access to them by us continually investing in our global presence and the availability of our products.
We seek to drive positive global health outcomes in the fields of digestive and metabolic medicine by:

• Addressing unmet medical needs and access barriers
• Increasing the speed and expanding the breadth of patient access  
• Pursuing excellence across the entire value chain
• Understanding the long-term impacts of scientific advances

Scope of the focus area
We aim to promote the accessibility of medicines for diverse, equitable, and inclusive patient populations through comprehensive company policies and programs, which encompass core pricing principles and access programs.

Strategic approach
We are committed to addressing barriers to access and affordability. We believe that the four key principles driving sustainable affordability include: 

• Sustainability: Ensuring both the healthcare system and our research-based family business continue to function effectively
• Value: Reflecting the clinical benefit of our medicines to patients, their broader impact on society, and the economic value for the healthcare system by reducing the need for additional medical intervention
• Access: Collaborating with payers and providers to enable sustainable access to medicines across our entire product portfolio
• Flexibility: Supporting pricing flexibility to accommodate differences in the needs of healthcare system and affordability